The PD-1 inhibitor sasanlimab showed anti-tumor activity and manageable safety in combination with BCG induction and maintenance compared with standard of care in patients with BCG-naïve high-risk ...
Non–muscle-invasive bladder cancer (NMIBC), seen in about 75% of newly diagnosed patients, is confined to the urothelial lining of the bladder and poses no immediate threat to life. However, almost 40 ...
In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a leading biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
UroGen Pharma’s Zusduri (mitomycin) has continued to show benefit after two years in patients with non-muscular invasive bladder cancer (NMIBC). In the Phase III ENVISION trial (NCT05243550), duration ...
Presents 18-month duration of response (DOR) data from the ENVISION study Analyzes the impact of tumor burden or focality in recurrent LG-IR-NMIBC, a substudy from ENVISION Reports ENVISION and ATLAS ...
SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals presented the first results from an ongoing Phase 3 trial in Japan assessing the efficacy and safety of nadofaragene firadenovec in ...
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results